Formulation: 50 mM Tris-HCl, pH 7.6, with 100 mM sodium chloride and 10 mM calcium chloride
Purity: ≥85% estimated by SDS-PAGE
Shelf life (days): 365
Notes: Secretory phospholipase A2 (sPLA2) (Type IIA) is a calcium-dependent PLA2 superfamily member that is encoded by PLA2G2A in humans.{56210} It is composed of a highly-conserved calcium-binding loop, a catalytic domain, sPLA2 Type I- and II-specific disulfides that provide stability, and a C-terminal extension but lacks the N-terminal signal peptide found in sPLA2 (Type IB) and sPLA2 (Type X). sPLA2 (Type IIA) is expressed in platelets, synovial fluid, vascular smooth muscle cells, adipose tissue, the liver, and the gut.{65319,4588} sPLA2 (Type IIA) functions in a cell- and tissue type-specific manner, preferentially hydrolyzing bacterial membrane phosphatidylglycerol (PG) and phosphatidylethanolamine (PE) as a mechanism of host defense. sPLA2 (Type IIA) is upregulated at sites of acute and chronic inflammation where it generates lysophosphatidic acid and arachidonic acid, which is further metabolized to inflammatory lipid mediators and a variety of eicosanoid autocrine and paracrine signaling molecules.{65320} Plasma levels of sPLA2 (Type IIA) are associated with the presence of sepsis and are increased in patients with rheumatoid arthritis, acute coronary syndrome, asthma, or inflammatory bowel disease (IBD). Cayman's sPLA2 (human, recombinant Type IIA) protein contains an asparagine to alanine substitution at position 1 to ensure proper removal of the N-terminal methionine during protein expression. Cayman's sPLA2 (human, recombinant Type IIA) can be used for enzyme activity assays. The specific activity of Cayman’s sPLA2 (human, recombinant Type IIA) was established using Cayman’s sPLA2 Assay Kit (Item No. 765001) with 1.48 mM 1,2-bis(heptanoylthio) glycerophosphocholine (Item No. 62235) as the substrate.
English
Deutsch
